Related Experiment Video
Updated: May 25, 2026

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
Published on: April 3, 2026
Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer
Manfred Kaufmann1, Thomas Karn, Eugen Ruckhäberle
1Department of Obstetrics and Gynecology and Breast Unit, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60 590, Frankfurt, Germany. M.Kaufmann@em.uni-frankfurt.de
Abstract:
The major aim of neoadjuvant systemic therapy is to improve prognosis by individualizing treatment. The proven benefits of neoadjuvant systemic therapy include reducing tumor burden, higher breast-conserving surgery, and the possibility of in vivo monitoring of response to treatment. Other goals of neoadjuvant treatment are the detection of new prognostic and predictive biomarkers and the investigation of new drugs and imaging modalities. Although many prospective trials have answered important questions regarding neoadjuvant systemic therapy, several topics remain controversial.
Related Concept Videos
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
